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Abstract. Neurocysticercosis (NCC), caused by Taenia solium larvae that reside in the central nervous system, results
in serious public health and medical issues in many regions of the world. Current diagnosis of NCC is complex requiring
both serology and costly neuroimaging of parasitic cysts in the brain. This diagnostic pipeline can be problematic in
resource-constrained settings. There is an unmet need for a highly sensitive and clinically informative diagnostic test to
complement the present diagnostic approaches. Here, we report that T. solium–derived cell-free DNA is readily de-
tectable in the urine of patients with the subarachnoid and parenchymal forms of NCC, and discuss the potential utility of
this approach in enhancing and refining T. solium diagnostics.
INTRODUCTION
Taenia solium is endemic in regions of Latin America, sub-
Saharan Africa, and Asia where pigs are raised under semi-
feral conditions. Although the adult form of this parasitic
cestode resides in the intestine, the tissue migrating T. solium
larvae can invade the brain resulting in neurocysticercosis
(NCC), a life threatening and debilitating form of the infection.1
Whereas detection of the intestinal infection with adult tape
worms is straight forward, definitive diagnosis of the central
nervous system (CNS) form of the disease is more difficult as
it requires neuroimaging of parasitic cysts in the brain.1 The
number of parasite cysts, their position in the brain, and other
factors are used to devise patient-specific management
plans, and an important step in this process is the efficient,
often field-based, identification of those individuals who are
candidates for costly neuroimaging.1 Presently, this is carried
out by the detection of antibodies in blood or cerebro-spinal
fluid or the identification of circulating T. solium antigens.1–4
Although these diagnostic approaches have proven useful,
they suffer from a number of immunological and logistical is-
sues and suboptimal combinations of sensitivity and speci-
ficity.1 There is an unmet need for a highly sensitive and
clinically informative diagnostic test for NCC to complement
or replace current diagnostic approaches.
In the fields of cancer and infectious diseases, interest is
growing in the use of cell-free DNA (cfDNA) found in serum,
saliva, urine, and other body fluids for diagnosis of disease
andmonitoring the efficacy of interventions.5–7 Thedetection
of cfDNA has been demonstrated to be useful for the di-
agnosis of parasitic diseases including malaria, trypanoso-
miasis, leishmaniasis, schistosomiasis, strongyloidiasis, and
filariasis (reviewed in ref. 6). Here, we report that T. solium–
derived cfDNA is readily detectable in the urine of NCC pa-
tients and discuss the potential utility of this approach in
enhancing and refining T. solium diagnostics and assessing
intervention efforts.
MATERIALS AND METHODS
Sample collection. Following informed consent, urine
and blood samples were collected from 23 neuroimaging-
confirmed Peruvian NCC patients in accordance with ethical
approval certificate R-033-03-17 issued by the main Insti-
tution Review Board of the Universidad Peruana Cayetano
Heredia. In addition, five blood and urine samples from non-
infected volunteers were also obtained. Fresh urine (40 mL,
processed within 3 hours) was filtered through a filter paper
cone (12.5 cmWhatmanNo. 3), dried overnight, and stored in a
plastic bag with desiccant at 4C. An additional 3 mL of urine
from each patient was frozen at −20C for subsequent mag-
netic bead–based extraction of cfDNA using MagMAX© Cell-
Free DNA Isolation Kit (Life Technologies, Austin, TX).
Serology. Blood samples were assessed for the presence
of anti–T. solium antibodies using the enzyme-linked immune-
electro-transfer blot (EITB) assay4 and circulating T. solium
antigen using a monoclonal antibody-based ELISA3 at the
UniversidadPeruanaCayetanoHeredia and theCysticercosis
Unit in the Instituto de Ciencias Neurológicas, both in Lima,
Peru. Each sample was tested in duplicate and was consid-
ered positive if the value was ³ 3 standard deviations greater
than the mean of the negative controls.
Extraction of cfDNA from filter paper. Fifteen 1.0-mm
discs were punched from the central portion of the filter,
covered with 600 μL of water, incubated at 95C for 10 min-
utes, and then gently agitated overnight at room temperature.
The tubeswere centrifuged at 4,000 rpm for 5minutes and the
cfDNA in the supernatant was extracted using a QIamp Mini
Kit (Qiagen, Hilden, Germany) followed by quantitation using a
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NanoDrop (NanoDrop Technologies LLC, Wilmington, DE)
and storage at −20C.
Detection of cfDNA. We selected the best performing
primer set from nine different primer sets tested. The primer
set designated P1 (P1F-59-CACGTGGCAGGGTGTGAC-39;
P1R-59-AGGAGGCCAGTTGCCTAGC-39) amplified a 116-bp
fragment from the pTsol-9 gene described by Chapman et al.8
The ampliconwas sequence-verified andmatched 100%with
pTsol-9. Amplification was performed at a 15 μL final volume
that contained 7.5 μL of Taq 2× Master mix (New England
Biolabs, Ipswich, MA), 0.75 μL of each primer (10 μM), 1–2 μL
ofMgCl2, 1.5 μL of water, and 2 μL of cfDNA (8–20 ng/μL). The
polymerase chain reaction (PCR) conditions were: 95C for
10 minutes, 30–35 cycles at 95C for 1 minute, 57–59C for
1.5 minutes, 72C for 1 minute, and a final extension step of
72C for 5 minutes. The amplicon was assessed on a 2%
agarose gel. Each sample was assayed in duplicate and sam-
ples with noncongruent results were reanalyzed to establish
their status. Only samples that were PCR positive in both rep-
licates were considered to be positive for T. solium cfDNA.
Positivity was confirmed by sequencing the amplicons.
RESULTS
Based on neuroimaging and neurological interpretation, the
23patientswereclassifiedasharbouring subarachnoid, viable
parenchymal, or calcified parenchymal NCC (Table 1). Pa-
tients with subarachnoid NCC had moderate to severe dis-
ease and were part of a clinical trial to determine the efficacy
of drug treatment. The two parenchymal NCC patients each
carried a single viable brain cyst, one 1.0 cm and the other
1.7 cm in diameter. Calcified NCC patients were part of a
cohort study of resolved, nonviable NCC and presented
with between one and 11 parenchymal brain calcifications.
Whereas the EITB results for the presence of anti–T. solium
antibodies were positive for all subarachnoid and viable pa-
renchymal patients, most, but not all, of the patients were
positive for circulating parasite antigen. A lower proportion of
the five patients harboring calcified cysts were antibody and
circulating antigen–positive.
The results for cfDNA analysis from the filter paper and the
magnetic bead protocols were largely congruent suggesting
that both of these DNA-capture approaches are viable alter-
natives for sample collection. The data presented in Table 1
represent a combination of the two capture methods. For the
subarachnoid and viable parenchymal NCC patients, 13/16
(81%) and 2/2 (100%), respectively, had detectable levels of
T. solium cfDNA in their urine. Of interest, 2/5 (40%) patients
with calcified cysts in the brain had detectable cfDNA in their
urine, suggesting that these calcified deposits are releasing
parasite material or these two patients harboured viable cysts
in their somatic tissues. Although the overall sensitivity of
cfDNA detection in the urine was 74% (17/23), for the patients
harboring demonstrably viable parasites in the brain (sub-
arachnoid and parenchymal), the sensitivity of the cfDNA
detection was 83% (15/18). Negative controls were from
anonymous donors never exposed to T. solium who tested
negative for antibody, antigen, and cfDNA.
DISCUSSION
The standard for the diagnosis of NCC is neuroimaging
using computed tomography and magnetic resonance im-
aging. This is typically confirmed by serology using either the
EITB which detects antibodies directed against parasite-
derived glycan residues.4 Enzyme-linked immune-electro-
transfer blot has high sensitivity for patientswho harbor two or
more live cysts in their CNS, but sensitivity drops significantly
for lower parasite loads.1 Like all antibody-based diagnostic
approaches, the EITB is an indirect measure that cannot dis-
tinguish between CNS and somatic infection or between
current infections and past exposure. Thus, EITB serology is
usually supported with a second test based on detection of
circulating parasite antigen in the blood. Themostwidely used
assay is a monoclonal antibody-based ELISA that detects a
circulating parasite antigen, however this test is limited by its
modest sensitivity in patients with a low number of CNS
cysts.1 Thus, there is a need for an additional diagnostic ap-
proach that can facilitate the reliable diagnosis of T. solium
CNS infection in the clinic and in the field.
Thepresenceof parasite-derivedcfDNA in thebodyfluidsof
patients has been demonstrated for a number of parasitic in-
fections6 and detection of cfDNA in the urine has been shown
to be a sensitive and specific diagnostic approach for several
helminth infections.9–12 Although T. solium cfDNA had been
detected in cerebrospinal fluid of NCC patients,13 our work is
the first to report that T. solium–derived cfDNA can be de-
tected in an easily obtained body fluid such as urine and serve
as a sensitive measure of infection. It is notable that 3/16
patients harboring subarachnoid cysts containing viable par-
asites were negative for cfDNA. Although it is possible that
TABLE 1
Results of the EITB, monoclonal antibody-based ELISA for detection
of circulatingTaenia soliumantigen (Ag-ELISA), and thePCR-based
detection ofT. soliumcfDNA fromurineon serumandurine samples
obtained from neuroimaging-confirmed NCC patients and controls
(SCAN-NEG)
NCC type EITB Ag-ELISA cfDNA
SUBARACHNOID + + +
SUBARACHNOID + + +
SUBARACHNOID + + +
SUBARACHNOID + + +
SUBARACHNOID + + +
SUBARACHNOID + − −
SUBARACHNOID + + +
SUBARACHNOID + + +
SUBARACHNOID + + +
SUBARACHNOID + + +
SUBARACHNOID + + +
SUBARACHNOID + + +
SUBARACHNOID + − −
SUBARACHNOID + + +
SUBARACHNOID + + −
SUBARACHNOID + + +
PARENCHYMAL + + +
PARENCHYMAL + + +
CALCIFIED + − +
CALCIFIED + + −
CALCIFIED − − −
CALCIFIED + − +
CALCIFIED − − −
SCAN-NEG − − −
SCAN-NEG − − −
SCAN–NEG − − −
SCAN-NEG − − −
SCAN-NEG − − −
cfDNA = cell-free DNA; EITB = enzyme-linked immune-electro-transfer blot; NCC =
neurocysticercosis.
+ and − indicate that the outcome of the assay was positive or negative, respectively.
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these represent a subset of patients that do not pass parasite
cfDNA in the urine, it is also possible that these patient’s
samples have cfDNA that is derived from other regions of the
parasite’s genome. Incorporating additional T. solium cfDNA
targets in a multiplex version of the assay could expand the
sensitivity of this diagnostic approach.
As with most infections, it is important to know if a
T. solium–infected patient is cured after treatment. Estimates
for thehalf-life of cfDNA in thebloodof humans rangebetween
4 minutes and 12 hours.14 Assuming that the immediate up-
stream source of cfDNA in the urine is the cfDNA from the
blood, this short half-life strongly suggests that detection of
parasite-derived cfDNA in the urine reflects the presence of
parasites and its absence could be used as a sensitive mea-
sure of the effectiveness of chemotherapy efforts. Indeed,
cfDNA-positive Schistosoma haematobium patients tested
negative 2 weeks after receiving praziquantel.9
There is a need for new diagnostic methods to better iden-
tify patients who harbor T. solium in the CNS so they can be
assessed by neuroimaging and their disease properly man-
aged. Although serology- and urine/cfDNA-based assays have
utility in the identification of infected individuals, the current
forms of these assays are not capable of discriminating somatic
from CNS involvement. Thus, additional refinements to these
assays will be necessary to confirm that patients harbor para-
sites that have localized to the CNS. Recent advances in the
identificationof biomarkers forCNS inflammation in the context
of a spectrum of brain diseases have demonstrated that these
markers are detectable in the urine of patients.15–17 Combining
cfDNA analysis with identification of biomarkers of CNS in-
flammation holds the potential for a sensitive and specific ap-
proach for the diagnose NCC from a single urine sample.
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